Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION In a safety team sitting on a new disproportionate signal, advisory-committee question list that exposes a weak secondary endpoint is the evidence after a boxed-warning proposal from the review division. Regulatory-affairs lead has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways close using advisory-committee question list that exposes a weak secondary endpoint.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after a boxed-warning proposal from the review division. 2. Keep Pause the pathway in force until advisory-committee question list that exposes a weak secondary endpoint is completed after a boxed-warning proposal from the review division for regulatory-affairs lead. 3. Treat advisory-committee question list that exposes a weak secondary endpoint as Escalate safety review because both readings appear after a boxed-warning proposal from the review division. 4. Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the decision the 505(b)(2) bridge is turns on in advisory-committee question list that exposes a weak secondary endpoint.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 2. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against a boxed-warning proposal from the review division and write the one fact that would move the 505(b)(2) bridge is for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (advisory-committee question list that exposes a weak secondary endpoint after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for regulatory-affairs lead in a safety team sitting on a new disproportionate signal.